Maraviroc (MVC), the only CCR5 inhibitor available to treat HIV infection, is active only against HIV strains which have tropism for this receptor, and not for CXCR4 or mixed tropism (CCR5/CXCR4) [111]. The gene discussed is CCR5; the disease is HIV infectious disease.